166981-13-1

Basic information

• Product Name: 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione
• Synonyms: 1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione; 1H-Purine-2,6-dione, 1-(11-(dodecylamino)-10-hydroxyundecyl)-3,7-dihydro-3,7-dimethyl-
• CAS NO: 166981-13-1
• Molecular Formula: C₃₀H₅₅N₅O₃
• Molecular Weight: 533.7894
• Mol File: 166981-13-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 691.4°C at 760 mmHg
• Flash Point: 371.9°C
• Density: 1.09g/cm³
• Vapor Pressure: 4.54E-20mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: -20°
• Solubility: Soluble in DMSO (up to 25 mg/ml)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
• CAS DataBase Reference: 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(166981-13-1)
• EPA Substance Registry System: 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione(166981-13-1)

Safety Data

• Hazardous Substances Data: 166981-13-1(Hazardous Substances Data)

Usage

Description

1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione, also known as CT-2584, is a cytotoxic agent that disrupts phospholipid biosynthesis by inhibiting CTP:choline-phosphate cytidylyltransferase. This leads to an increase in phosphatidylinositol and a decrease in phosphatidylcholine, causing a loss of membrane integrity, particularly in mitochondria and endoplasmic reticulum. CT-2584 has demonstrated activity against a broad spectrum of tumor cell lines, including multi-drug resistant ones.

Uses

Used in Oncology:
CT-2584 is used as a cytotoxic agent for the treatment of various types of cancer. Its mechanism of action involves the alteration of phospholipid metabolism, leading to the disruption of membrane integrity in cancer cells, particularly in mitochondria and endoplasmic reticulum. This results in the inhibition of tumor growth and the killing of cancer cells. CT-2584 has shown activity against a wide range of tumor cell lines, including those that are multi-drug resistant.
Used in Drug Development:
CT-2584 is used in the development of new anticancer drugs. Its unique mechanism of action and broad-spectrum activity against various tumor cell lines make it a promising candidate for further research and development. 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione can be further optimized and combined with other therapeutic agents to enhance its efficacy and overcome drug resistance in cancer treatment.

References

1) Finney?et al. (2000),?Pharmacological Inhibition of Phosphatidylcholine Biosynthesis is Associated with Induction of Phosphatidylinositol Accumulation and Cytolysis of Neoplastic Cell lines; Cancer Res.,?60?5204 2) Cheeseman?et al. (2000),?Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumors; Br. J. Cancer,?83?1599

Upstream product

• 156918-66-0 1-(10,11-oxidoundecanyl)-3,7-dimethylxanthine 
• 124-22-1 n-Dodecylamine 

Relevant articles and documents

Manufacture of polyglutamate-therapeutic agent conjugates

The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.